WINT (Windtree Therapeutics, Inc.) Enterprise Value-to-Revenue Coefficient

Windtree Therapeutics Inc. (WINT) - corporate logo

Windtree Therapeutics (WINT) develops drugs in the US to stabilize patients with acute heart failure. The change in the EV/Sales valuation on the GURU.Markets service confirms the asset's dynamics, where becomes the new value of the indicator. The business relies on a sovereign cycle independent of macroeconomics, while a team of top-tier cardiologists is retained through test autonomy and clinical options.

Windtree - WINT EV/Sales Multiple (period 07/04/2022 - 11/20/2026)

Windtree Therapeutics - analytical breakdowns and key metrics (WINT)

- business market valuation indicators:
Initial company analysis:Windtree Therapeutics Inc.
Product sample of Windtree

For Windtree Therapeutics (WINT), an innovator in acute heart failure therapy, this indicator links the business's market value to its sales volume. By analyzing the enterprise value-to-revenue ratio, an investor assesses the total enterprise value (EV) relative to operating income, which offsets the impact of debt load and determines the company's fundamental stability within the hospital cardiology segment.